Get started

Chinastocks

Bullish Charts - Online Learning in ChinaRYB Education, Inc. provides early childhood education service in the People's Republic of China. The company offers kindergarten services to 2-6-year-old children; and play-and-learn centers services for the joint participation of 0-6-year-old children and their adult family members to promote children's development, foster bonding with family, and prepare them for their entry into kindergartens and primary schools. It also develops and sells educational products and services, such as teaching aids, educational toys, at-home educational products, and school uniforms through franchisees and other business partners, as well as directly to a market of families. As of December 31, 2019, it operated 100 directly operated and 250 franchise kindergartens; and 6 play-and-learn centers. The company was formerly known as Top Margin Limited and changed its name to RYB Education, Inc. in June 2017. RYB Education, Inc. was founded in 1998 and is based in Beijing, China. Daily Chart is Bullish Broke out above the cloud yesterday. Indicators are Bullish Long DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
RLong
by HotCharts
2
Baidu: Deep Pullback to Key Support and a Golden CrossChinese stocks have been surging this year as investors embrace the country’s flourishing digital economy. However, one of its most established names hasn’t broken out yet: Baidu – “the Google of China.” BIDU entered the current environment in a weak place after years of revamping its search and advertising business. However it’s reported strong results in the last four quarters. It also surged in June on a report that Tencent may increase its stake in Iqiyi , which is majority owned by BIDU. BIDU has pulled back and digested a lot of its gains in the last two weeks. It’s returned to the $118-120 area where it’s consolidated and pivoted several times in the last year. The stock also just had a “Golden Cross,” with the 50-day simple moving average (SMA) rising up and through the 200-day SMA. This can reflect a long-term change in momentum – potentially interesting in a stock that’s lost more than half its value since July 2018.
NASDAQ:BIDULong
by TradeStation
Moderna in Trouble - ABUS Wins Lawsuit Tied to COVID-19 DrugArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. AFTER HOURS BREAKING NEWS Moderna stock tumbled late Thursday after the biotech lost a patent battle that may jeopardize the financial future of its coronavirus vaccine. Moderna (MRNA) challenged patents held by Arbutus Biopharma (ABUS) covering lipid nanoparticle, or LNP, technology. Lipid nanoparticles are the delivery system for messenger RNA drugs, including Moderna's coronavirus vaccine, which is known as mRNA-1273. Despite the company's contention, the ruling could cut into profits on any Moderna drug, including mRNA-1273, says SVB Leerink analyst Mani Foroohar. "Revenue concentration in (the coronavirus vaccine) is a central feature of the investment case for Moderna shares," Foroohar said. "Any meaningful royalty burden could hamper Moderna's pricing flexibility and margin profile vs. other players in the SARS-CoV-2 vaccine market." Foroohar called the decision in Arbutus' favor "a disappointing turn for Moderna." "This decision opens the door to a fascinating (and likely protracted) period of investor controversy and debate around the implications of any potential infringement of claims by Arbutus regarding Moderna's use of Lipid Nanoparticle delivery technology, and any further actions Moderna may take to defend their own (intellectual property) position and freedom to operate," he said. NEWS: www.investors.com Where's ABUS going? To $100.00 ...??? On the monthly chart, it looks like $9.00 might be the next stop..? At this point, I am not sure if there is a top right now for ABUS. The news is huge for ABUS and could entitle ABUS to billions in profits and revenue from the COVID-19 vaccine. Intelligent comments welcome. DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ABUSLong
by HotCharts
4
Timeline: NIO vs. TSLA = NIO Target $350 to $500Don't shoot the messenger! I have a timeline of Tesla below which should put a price target on NIO North of $400 to $500 a share. www.thestreet.com As we stand today, NIO is much more successful than Tesla ever was and at this time, or there a bouts, compared to Tesla at or around the same time period in production & sales, Tesla was trading north of $360 a share and only delivered 2,400 cars compared to NIO delivering over 46,000 vehicles. "Entering 2018 Tesla faced several difficulties. Missed predictions had led investors to dump the company's stock, and in the middle of 2017 it lost more than 5% of its value in a collapse worth $12 billion. By January, 2018 Tesla was producing its Model 3 sedans at a fraction of the rate it had anticipated. Over a three-month period the company managed to finish and ship 2,400 cars after promising consumers and investors that it could complete more than 5,000 per week." On 07/02/2020, NIO announced as of June 30, NIO delivered 46,082 vehicles with 14,169 already delivered for 2020. These sales figures topple what Tesla sold and at or around the same time period, Tesla stock spiked to around $389.61. These are real figures from the Tesla timeline I have listed herein and using monthly stock charts for Tesla's stock price at that time period. NIO is also in much better financial condition than Tesla ever was at or around the same time in the production and sales cycle / timeline. Folks, when you look at the monthly stock prices for Tesla, and compare the timeline link I have herein, NIO is extremely cheap and deeply undervalued at current levels. Also, NIO has the Chinese Government behind them. Tesla, at or around when the company started, only raised $500 million from a DOE loan and Tesla was burning cash like water. NIO just raised almost $1 Billion in funding. NIO is financially in a better place than what Tesla ever was. The way I see it, the Chinese Government will not let NIO fail to Tesla, a USA auto company. In my opinion, after researching Tesla vs. NIO, I personally think NIO should be trading at or around $350 to $500 a share with their financial and sales figures. Best of luck longs! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:NIOLong
by HotCharts
12
JD.com: Pullback in Chinese Momentum StockThis one is short and simple: JD.com just had its first decent pullback since it started running in May. JD has a few things going for it. First, the Beijing-based e-commerce stock spent almost all of June consolidating on either side of $60. It ripped over that level after the Independence Day weekend and has now retraced that surge. Will the old resistance zone around $60 become support? Second, JD has tested and held its 21-day exponential moving average (EMA). The last time it did that was way back on May 6. Third is the relative strength . Money has streamed into Chinese technology stocks because of changes in global indexes and a quicker recovery from coronavirus.
NASDAQ:JDLong
by TradeStation
$CMCM can rise in the next daysContextual immersion trading strategy idea. Cheetah Mobile Inc. operates as a mobile Internet company. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,71; stop-loss — $2,41. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NYSE:CMCMLong
by KozakHlib
$CPHI can rise in the next daysContextual immersion trading strategy idea. China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $0,69; stop-loss — $0,65. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
AMEX:CPHILong
by KozakHlib
Bullish Charts - In-Home COVID-19 TestCo-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah. Daily Chart MACD, RSI & STOCHASTIC are turning up, Bullish Volume is also picking up steam. On 06/09/2020, CODX announced the company will be added to the Russell 2000 and 3000 Indexes On 05/28/2020, Analysts set price targets at $30 and $36 On 05/26/2020, CODX said its Logix Smart Covid-19 test kit was used to demonstrate that the SARS-CoV-2 virus can be detected in cancer tissue of coronavirus patients. On 05/18/2020, Price Target Raised to $35.00 The stock looks like it's on the verge of breaking out much higher. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:CODXLong
by HotCharts
Bullish Charts - COVID-19 Play, N95 Masks, Robust EarningsAlpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials. The Disposable Protective Apparel segment provides shoecovers, bouffant caps, gowns, coveralls, lab coats, hoods, and frocks, as well as face masks and face shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; pharmaceutical markets; and building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada. Today looks like a solid break-out in a down market. Alpha Pro is part of a $15 Billion dollar industry. With N95 masks in high demand, I think there's only one way this stock can go, UP... On 5/6/2020, the company reported earnings of $0.39 up from $0.09. Revenue spiked with 47.5% sales growth. On 5/6/2020, The company announced it was debt free. Not many companies can say they're debt free. 52-Week high is around $41.00 Last earnings report was a blockbuster! The company blew past Wall Street estimates and I think they'll continue blowing past estimates into the future. Indicators are Bullish. Daily Chart looks great. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
AMEX:APTLong
by HotCharts
$QD can rise in the next daysContextual immersion trading strategy idea. Qudian Inc. provides online small consumer credit products in the People's Republic of China. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $1,89; stop-loss — $1,79. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NYSE:QDLong
by KozakHlib
COVID-19 Play - Closed Over $5.00 - July is Here!On May 15, 2020, Sorrento had this to say about the COVID-19 vaccine they are working on... “We’re actually so impressed with the data,” Ji said. “One of the antibodies is so powerful that at a very low concentration it is able to 100% completely prevent infection or inhibit the infection. In our studies, not even one virus escaped from the antibody.” "Phase 1 trial could start within 1st few days of July" - (It mentions this date in the article) "We anticipate having enough material to start Phase 1 trial in patients in the ICU within two (2) months." - (The article I listed was published in May.) Ji was talking about the COVID-19 vaccine they have been working on with Mount Sinai Health System & the University of Texas Medical Branch which has access to the live virus. Anyone thinking this is not the real deal, you might want to think again. Moderna's stock is sitting at $63.04 (After Hours) - What does Moderna have that Sorrento doesn't have? In the article listed herein, Sorrento said "within 2 months..." We are within those two (2) months now. (End of June or July) Link to article: www.biospace.com Today, SRNE broke out above $5.00 On the daily chart, as of today, the Volume spiked, and the MACD, RSI, Stochastic & Accumulation are all Bullish or trending up Bullish. Is news forthcoming? After watching what the stock price of Moderna did and looking at Sorrento trading at $5.12, to me, the reward far outweighs any risk. Also, I believe Sorrento is waiting for an Emergency Use Label on their COVID-19 test that can give you a positive or negative within 8 minutes. Does Moderna have a test? I don't think so. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
SLong
by HotCharts
3
$SY can rise in the next daysContextual immersion trading strategy idea. So-Young International Inc. operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $11,31; stop-loss — $10,76. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:SYLong
by KozakHlib